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The convergence of advances in medical science, human biology, data science, and
technologyhasenabled thegenerationofnew insights into thephenotypeknownas
“diabetes.” Increased knowledge of this condition has emerged from populations
around theworld, illuminating thedifferences in howdiabetes presents, its variable
prevalence, and how best practice in treatment varies between populations. In
parallel, focus has been placed on the development of tools for the application of
precision medicine to numerous conditions. This Consensus Report presents the
American Diabetes Association (ADA) Precision Medicine in Diabetes Initiative in
partnership with the European Association for the Study of Diabetes (EASD),
including its mission, the current state of the field, and prospects for the future.
Expert opinions are presented on areas of precision diagnostics and precision
therapeutics (including prevention and treatment), and key barriers to and oppor-
tunities for implementation of precision diabetes medicine, with better care and
outcomes around the globe, are highlighted. Cases where precision diagnosis is
already feasible and effective (i.e., monogenic forms of diabetes) are presented, while
the major hurdles to the global implementation of precision diagnosis of complex
forms of diabetes are discussed. The situation is similar for precision therapeutics, in
which the appropriate therapy will often change over time owing to the manner in
which diabetes evolves within individual patients. This Consensus Report describes a
foundation for precision diabetes medicine, while highlighting what remains to be
done to realize its potential. This, combinedwith a subsequent, detailed evidence-
based review (due 2022), will provide a roadmap for precision medicine in diabetes
that helps improve the quality of life for all those with diabetes.
RATIONALE FOR PRECISION MEDICINE IN DIABETES
The practice of medicine centers on the individual. From the beginning, the physician
has examined the patient suffering from illness, ascertained his/her signs and
symptoms, related them to themedical knowledge available at the time, recognized
patterns that fit a certain category and, based on the practical wisdom accumulated
via empirical trial and error, applied a given remedy that is best suited to the
situation at hand. Thus, the concept of precision medicine, often defined as
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providing the right therapy for the right
patient at the right time, is not novel.
What has changed radically is our ability
to characterize and understand human
biological variation through 1) assess-
ment of the genetic andmetabolic state,
2) leveraging data to inform disease cat-
egories, and 3) science-guided preventive
and treatment decisions tailored to spe-
cific pathological conditions. Coupling
these with detailed information about
lifestyleandenvironment,availablethrough
digital devices and technologies that
collect those measures, as well as data
abstracted from electronic medical re-
cords, present unparalleled opportuni-
ties to optimize diabetes medicine.
Diabetes mellitus is diagnosed by the
presence of hyperglycemia that is higher
than a threshold blood glucose concen-
tration which predisposes to microvas-
cular end-organcomplications.However,
hyperglycemia is the end product of nu-
merouspathophysiologicalprocesses that
often emerge over many years and con-
verge on the inability of the pancreatic
b-cells to secrete enough insulin to meet
the demands of target tissues. In clinical
practice, absolute insulin deficiency can
be detected from the autoimmune de-
struction of b-cells in type 1 diabetes
(T1D), which represents ;10% of all
diabetes cases. Making the diagnosis of
T1D is critical for survival, given the
therapeutic requirement of exogenous
administration of insulin. However, less
commonly, hyperglycemia might derive
from an inherited or de novo loss of
function in a single gene (e.g., mono-
genic diabetes, comprising 2–3% of all
diabetes diagnosed in children or young
adults). Diabetes can also appear after
pancreatitis or organ transplantation,
during pregnancy, or as a result of cystic
fibrosis.Most individualswith diabetes,
however, are likely to be diagnosedwith
type 2 diabetes (T2D), which includes
defects in one or (more often) multiple
physiological pathways (e.g., b-cell
insufficiency, fataccumulationormiscom-
partmentalization, inflammation, incretin
resistance, dysfunctional insulin signaling).
Our modern capacity to comprehen-
sively interrogate diverse axes of biology
has facilitated the approach of studying
anindividualtoinfergeneralprinciples,from
which a discrete treatment plan is se-
lected. These axes include developmental/
metabolic context, genomic variation,
chromatin signals that mark genes as
active or repressed in tissues, expressed
transcripts, biomarkers of disease, and in-
creasedknowledgeof lifestyle/environmental
risk factors. Parallel advances in compu-
tational power and analytical methods
required to appropriately interrogate
“big data” are driving insights that may
radically transform the practice ofmed-
icine. Yet, at this time, the individual
physicianoften lacks the timeand training
needed to incorporate these insights into
medical decision making. Thus, the trans-
lation of the rapidly accumulating new
knowledge into practice requires careful
evaluation and translational strategies
involving specialist training, education,
and policy considerations.
The failure to adequately understand
thediversemolecular andenvironmental
processes that underlie diabetes and our
inability to identify the pathophysiolog-
ical mechanisms that trigger diabetes in
individual patients limit our ability to pre-
vent and treat the disease. Public health
strategies have struggled to slow the ep-
idemic, even in countrieswith the greatest
financial and scientific resources. Pharma-
cological therapies,comprising12different
drugclasses currently approvedby theU.S.
Food andDrug Administration (FDA),may,
at best, control blood glucose and modify
disease coursebutdonotprovide a cureor
result in the remission of disease. More-
over, these agents are sometimes pre-
scribed based on nonmedical considerations
(cost, side effects, patient preference, or
comorbidities), which may overlook the
biological mechanism. Thus, more people
are developing diabetes worldwide and
have disease progressing to complica-
tions, incurring a significant health care
burden and cost.
There are, however, several reasons
for hope. First, diabetes caused by single
gene defects can be characterized and
targeted therapies are particularly effec-
tive (1,2). Second, islet autoantibody bio-
markers and genomic risk have clarified
autoimmune diabetes from other forms
of the disease (3,4), thereby facilitating
immune intervention trials and preonset
monitoring to reduce risk of severe com-
plications and aiding in detection of en-
vironmental triggers (5). Third, multiple
biomarkers and genetic variants have
been shown to alter risk of T2D, re-
vealing previously unsuspected biolog-
ical pathways and providing new targets.
Fourth, T2D has been shown to be a
complex combination of multiple con-
ditions andprocesses, definedbyprocess-
specific subgroups in which individuals
with extremeburdens of risk in particular
pathways reside and for whom a specific
therapeutic approach may be optimal
(6). Finally, the tools, resources, and
data now exist to determine the bio-
logical and lifestyle/environmental pre-
dictors of drug response, as measured
by a variety of clinical outcomes (7).




ise of reducing the enormous and grow-
ing burden of diabetes worldwide. To
address this, the Precision Medicine in
Diabetes Initiative (PMDI) was launched
in 2018 by the American Diabetes Asso-
ciation (ADA), in partnership with the
European Association for the Study of
Diabetes (EASD). The PMDI has part-
nered subsequently with other organ-
izations (the U.S. National Institute of
Diabetes and Digestive and Kidney Dis-
eases [NIDDK] and JDRF).
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The mandate of the PMDI is to establish
consensus on the viability and potential
implementation of precision medicine for
the diagnosis, prognosis, prevention, and
treatment of diabetes, through expert con-
sultation, stakeholder engagement, and
systematic evaluation of available evidence.
This mandate is pursued in order to realize
a future of longer, healthier lives for people
with diabetes.
The PMDI is focused on assessing
evidence, promoting research, providing
education, and developing guidelines for
the application of precision medicine in
diabetes. The 2019 ADA Scientific Ses-
sions (held in June 2019) sponsored a
research symposium focused on preci-
sionmedicine, followed by a PMDI stake-
holder meeting (held in October 2019)
that was attended by experts in areas
germane to precision diabetes medicine
from around the world. Future PMDI
symposia will extend the themes of pre-
cision diabetes medicine during the
2020 ADA Scientific Sessions and EASD
Annual Meeting. In the coming years,
educational approaches to translate the
science into practice will be the target of
a series of postgraduate education sym-
posia. A global clinical research network
focused on precision diabetes medicine
is also being planned, along with other
education and information dissemination
activities (see Fig. 1 for an overview of key
objectives).
The purpose of the work underlying
the ADA/EASD PMDI consensus reports,
of which this is the first, is to define
relevant terminology (Text Box 1) and
review the current status of diagnostics
and therapeutics (prevention and treat-
ment) in diabetes, including key areas of
opportunity and where further inquiry is
needed (Text Boxes 2–4). Particular focus
is placed on elucidating the etiological
heterogeneity of diabetes, which involves
a combination of approaches including
contemporaneous measures of risk fac-
tors, biomarkers, and genomics, as well as
lifestyle and pharmacological interven-
tions. Monogenic diabetes is one of few
areas where precision diabetes medi-
cine has been proven feasible and is
practiced (as discussed at a recent Di-
abetes Care Editors’ Expert Forum; M.C.
Riddle, personal communication). This
first Consensus Report does not seek
to address extensively the role of pre-
cision medicine in the complications of
diabetes, which is a topic for future
evaluation. In addition, we donot discuss
diabetes digital device technology, as
this is addressed in a joint ADA/EASD
consensus report (8,9). A second PMDI
consensus report will be published docu-
menting the findings of a systematic
evidence review, focusing on precision
diagnostics and precision therapeutics
(prevention and treatment).
An Executive Oversight Committee,
comprising representatives from the
founding organizations, ADA (L.P.) and
EASD (J.J.N.), and the two co-chairs of
the initiative (P.W.F. and S.S.R.), provide
PMDI governance. The Executive Over-
sight Committee is responsible for en-
suring that the PMDI activities are executed.
Leadership and direction of the PMDI are
provided bymembers of the PMDI Steer-
ing Committee, currently composed of
academic leaders in precision diabetes
medicine from the U.S. (W.K.C., J.C.F.,
J.M.N.)andEurope(A.T.H.,M.I.M.,E.R.P.),
a representative fromNIDDK (C.G.L.), and
the ExecutiveOversight Committeemem-
bers (L.P., J.J.N., P.W.F., S.S.R.). The Steer-
ingCommittee is responsible forproviding
guidance for PMDI activities and engages
in developing precisiondiabetesmedicine
education, drafting consensus statements,
and building interest/working groups to
achieve its mission. The Executive Over-
sight Committee and the Steering Com-
mittee work closely together under the
banner of the PMDI Task Force.Member-
ship of the Steering Committee will ex-
pand to include experts from around the
world and across multiple areas of ex-
pertise germane to the topic of precision
diabetes medicine.
Work for this Consensus Report began
at theOctober 2019 stakeholdermeeting
inMadrid. The meeting included presen-
tations and roundtable discussions. At
the conclusion of the meeting, a writing
group meeting attended by the PMDI
Task Force and stakeholders was held to
determine what should be addressed in
the Consensus Report. Following the meet-
ing,consensuswasreachedbythePMDITask
Force throughbimonthly calls andelectronic
Figure 1—PMDI activities. PM, precision medicine; RFA, research funding announcement.
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communication. Relevant experts out-
side of the Task Force were asked to
contribute sections as needed. The Con-
sensus Report was then peer reviewed
by experts in the field and by the clinical
committees of the founding organiza-
tions. The report was then submitted to
Diabetes Care and Diabetologia for si-
multaneous publication.
PRECISION DIABETES MEDICINE:
WHAT IT IS AND WHAT IT IS NOT
Precision diabetes medicine refers to an
approach to optimize the diagnosis, pre-
diction, prevention, or treatment of di-
abetes by integrating multidimensional
data, accounting for individualdifferences
(Text Box 1). The major distinction from
standardmedical approaches is the use of
complex data to characterize the individ-
ual’s health status, predisposition, prog-
nosis, and likely treatment response.
Precision medicine also focuses on iden-
tifying patients who, despite a diagnosis,
do not require treatment (or require less
thanmight conventionally be prescribed).
These data may stem from traditional
sources such as clinical records, as well
as from emergent sources of “big data”
such as individual medical records from
very large cohorts of patients; geomo-
bility patterns obtained from devices;
behavioralmonitors (e.g., actigraphy for
exercise and sleep assessments); ingest-
ible, subcutaneous, or wearable sensors
(e.g., for blood glucose monitoring); and
genomicandother ’omicsdata. Integration
of patient preferences, patient-centered
outcomes, cost-effectiveness, and shared
decision making will guide how pre-
cision diabetes medicine is formulated
and applied.
There are several terms sometimes
used interchangeablywith precisionmed-
icine, including “personalized medicine,”
“individualized medicine,” and “stratified
medicine.” The 2020 ADA Standards of
Medical Care in Diabetes (ADA SOC)
places considerable emphasis on the
personalization of diabetes medicine,
highlighting that “clinicians care for
patients and not populations” (10) (p.
S2). This reflects the appreciation of
individual differences with respect to
symptomatology, presentation, behaviors,
preferences, social circumstances, response
to treatment, comorbidities, or clinical
course. For precision diabetes medicine
to be effective, it must be tailored to the
individual. Thus, the ADA SOC instructs
the clinician to adapt guidelines to each
patient’s characteristics, circumstances,
and preferences, including the patient’s
food security, housing, and financial sta-
bility. InthecontextofthePMDI,this isnot
considered to be precision medicine;
rather, this final step in the process of
translating knowledge into practice is
personalized (or individualized) medi-
cine. In contrast, precision (or stratified)
medicineemphasizes tailoringdiagnostics
or therapeutics (prevention or treatment)
to subgroups of populations sharing sim-
ilar characteristics, thereby minimizing
error and risk while maximizing efficacy.
Includedwithin precision diabetesmed-
icine is the monitoring of disease pro-
gression using advanced technologies or
Text Box 1—Definitions
c Precision diagnosis involves refining the characterization of the diabetes diagnosis for therapeutic optimization or to improve prognostic clarity
using information about a person’s unique biology, environment, and/or context.
○ Precision diagnostics may involve subclassifying the diagnosis into subtypes, such as is the case in MODY, or utilizing probabilistic algorithms
that help refine a diagnosis without categorization.
○Careful diagnosis is oftennecessary for successful precision therapy,whether for preventionor treatment. This is truewhere subgroup(s) of the
populationmust be defined, within which targeted interventionswill be applied, and alsowhere one seeks to determinewhether progression
toward disease has been abated.
○Precisiondiagnosis canbe conceptualized as a pathway thatmoves through stages, rather than as a single step. Thediagnostic stages include1)
an evaluation of prevalence based on epidemiology, including age, or age at diagnosis of diabetes, sex, and ancestry; 2) probability based on
clinical features; and 3) diagnostic tests that are interpreted in the light of 1) and 2). A diagnosis in precision medicine is a probability-based
decision, typically made at a specific point in the natural history of a disease, and neither an absolute truth nor a permanent state.
c Precision therapeutics involves tailoring medical approaches using information about a person’s unique biology, environment, and/or context
for the purposes of preventing or treating disease (see Precision prevention and Precision treatment, below).
c Precision prevention includes using information about a person’s unique biology, environment, and/or context to determine their likely
responses to health interventions and risk factors and/or to monitor progression toward disease.
○ Precision prevention should optimize the prescription of health enhancing interventions and/or minimize exposure to specific risk factors for
that individual. Precision prevention may also involvemonitoring of health markers or behaviors in people at high risk of disease, to facilitate
targeted prophylactic interventions.
c Precision treatment involves using information about a person’s unique biology, environment, and/or context to guide the choice of an
efficacious therapy to achieve the desired therapeutic goal or outcome, while reducing unnecessary side effects.
○ Today, the objective of precision therapy is to maximize the probability that the best treatment of all those available is selected for a given
patient. It is possible that in the future, precision diabetes medicines will be designed according to the biological features of specific patient
subgroups, rather than for the patient population as a whole.
c Precision prognostics focuses on improving the precision and accuracy with which a patient’s disease-related outcomes are predicted using
information about their unique biology, environment, and/or context.
○ The focus of precisionprognostics includes predicting the risk and severity of diabetes complications, patient-centered outcomes, and/or early
mortality.
c Precision monitoringmay include the detailed assessment of biological markers (e.g., continuous glucose monitoring), behaviors (e.g., physical
activity), diet, sleep, and psychophysiological stress.
○ Precision monitoring can be achieved using digital apps, cutaneous or subcutaneous sensors, ingestible sensors, blood assays etc.
○ The intelligent processing, integration, and interpretation of the data obtained throughprecisionmonitoring are key determinants of success.
○ Precision monitoring may be valuable for precision prevention (e.g., in T1D), precision diagnostics (e.g., where diagnoses are based on time-
varying characteristics), and precision prognostics (e.g., where disease trajectories are informative of the development of key outcomes).
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considering how patient features affect
the reliability of assays. The application
of precision diabetesmedicinemay sub-
stantially reduce errors in diagnostic
(Fig. 2), therapeutic (Fig. 3), and prognostic
(Fig. 4) processes. For example, the in-
terrogation of large sets of longitudinal
clinical data could identify disease sub-
types and match the patient to others
with a similar disease profile; through
knowledge of treatment efficacy and
outcomes, more precise prognosis and
optimization of therapies for thispatient
byconcordancetosimilarsubgroupswould
emerge (Text Box 1 and Figs. 3 and 4).
PRECISION DIAGNOSTICS
What are the Requirements for
Precision Diagnosis?
Precision diagnostics (Text Box 2) em-
ploys methods to subclassify patients to
enable the successful application of pre-
cision medicine approaches (Fig. 2). This
will facilitate matching precise preven-
tion strategies and treatments to indi-
viduals either at risk for or diagnosed
with diabetes. Ideally, a precision diag-
nostic test should be 1) robust (high
test-retest reliability within and between
laboratories); 2) able to define a discrete
subgroup giving insights into disease
etiology, prognosis, and treatment response;
3) widely available; 4) easily performedwith
accepted norms for interpretation; 5) in-
expensive (or at least cost-effective); and
6) approved by regulatory authorities.
Precision diagnosis can be conceptu-
alized as a pathway that moves through
stages, rather than as a single step. The
diagnostic stages include assessing the:
c expected prevalence based on epide-
miology, including age, or age at di-
agnosis of diabetes, sex, and ancestry,
c probable clinical diagnosis using clinical
features and other data, and
Text Box 2—Precision diagnostics: background, barriers to implementation, and research gaps
c Type1diabetes.Bestdiagnostic resultsdependon integratingall diagnosticmodalities, notby relyingonpriorprevalence, clinical features,or test
results in isolation. Theage atwhich the initial islet autoantibody appears and the typeof autoantibody (e.g.,whichof the four primary antibodies
among ICA512, insulin, GAD, and ZnT8) may be important in defining etiological subtypes of T1D. The majority of the genetic risk of T1D is now
known,andthesensitivityandspecificityofaT1Dgenetic risk score (T1D-GRS)bothexceed80%.Despite this, ahighT1D-GRSwill have lowpositive
predictivevalue inpatientpopulationswhere theoverallprevalenceofT1D is low, suchas thoseaged.50yearswhendiabetes isdiagnosed. Itwill
likely provemost useful when the T1D-GRS is combinedwith clinical features and islet autoantibodies. At present, there is no immune-based test
sufficiently reproducible and robust that it can be used diagnostically.
c Type2diabetes.Categoriesbasedoncluster analysis atdiagnosis canprovide insights into likelyprogression, riskof complications, and treatment
response, which offer an exciting approach to subclassification of T2D. At this time, the available genetic data for T2D do not have sufficient
predictive accuracy to replace existing delineative approaches. Although the subcategorization of T2Dusing genetic data is informative regarding
theetiological processes that underlie thedisease, themethodsdescribed so far (6,101) arenot intended tobeused to subclassify a T2Ddiagnosis
nor are the existing genetic data sufficient for this purpose for the majority of individuals with T2D. Treatment response and progression can be
predicted from clinical features (137). An advantage of using clinical features for diagnosis of T2D is that they are widely available and easily
obtained (e.g., sex, BMI, HbA1c); however, a potential limitation is that they may vary over time.
c Barriers to implementation. One of several important translational barriers facing the proposed clustering approach for T1D and T2D is that
a fasting C-peptide measurement is required at the time of diagnosis, which is not routinely performed in clinical practice, and the reliability of
C-peptide assays varies considerably between laboratories (41). Another limitation is that the biomarkers used to define these clusters change
over timedependingon thedisease courseor its treatment, such that this approach canonly be applied tonewly diagnosed individuals, but not to
individuals years before disease onset or themanymillions of peoplewith long-standing diabetesworldwide.Moreover, the current approaches
for clustering in T2D require continuously distributed data to be categorized, which typically results in loss of power. Thus, thesemethods do not
yield good predictive accuracy, a major expectation in precision medicine, but this may change as the approach is refined.
c Research gaps. Based on limited ideal tests and uncertainty in etiology, more research is needed in T1D and T2D in order to define subtypes and
decide the best interventional and therapeutic approaches.
Text Box 3—Precision prevention: background, barriers to implementation, and research gaps
c Type 1 diabetes. In T1D, precision prevention mainly involves the optimization of monitoring methods, thereby facilitating early detection and
treatment. The reasons most prevention trials in T1D have not been effective may include failure to consider the individual’s unique T1D risk
profile (e.g., genetic susceptibility) and their unique response to the preventive agent (immune therapy or dietary intervention). Without
considering the unique genetic profiles of children, interventions aimed at preventing type 1 diabetes (e.g., dietary intervention or
immunotherapy) may be unlikely to succeed. Thus, precision prevention in T1D is likely to involve stratification of at-risk populations and
innovative monitoring technologies.
c Type 2 diabetes. T2D has many avenues for prevention; thus, the possibilities for precision approaches, possibly through tailoring of diet, are
broad. To date, prevention of T2D has focused on peoplewith prediabetes. To be cost-effective, it will likely be necessary to stratify the population with
prediabetes such that only those with other relevant risk factors are the focus of preventative interventions. Relevant risk factors may include lifestyle,
socioeconomic status, family history, ethnicity, and/or certain biomarker profiles, including genetics.
c Barriers to implementation. The effective implementation of precision prevention will require that appropriate technologies are available, the
general public has the willingness to embrace the approach and that those in greatest need can access precision prevention programs. A
communication plan used by the interventionalist and the patient’s perception of risk should be a focus of precision prevention strategies.
c Research gaps. There are critical areas of research required for implementation of precision prevention in diabetes, including determining for
whomonline care ismore effective than in-person care, the types of staff delivering the lifestylemodification programs, the impact of group and/
or individual interaction, andthe frequencyof suchsessions.There is alsouncertaintyabouthowbest toprovideandsustain lifestylemodification.
In addition, emphasis should be placed on identifying profiles that indicate the likely response to specific lifestyle interventions (focusing on
specific diets, exercise programs, and other behavioral factors) and sensitivity to risk factors (such as sleep disturbance, stress, depression, poor
diet, sedentary behaviors, smoking, certain drugs, and obesity).
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c modification by diagnostic tests that
are interpreted in the light of preva-
lence and diagnosis.
A diagnosis in precision medicine is a
probability-baseddecision, typicallymade
at a point in the natural history of a
disease, reflecting neither an absolute
truth nor a permanent state. Presenting
the degree of uncertainty in a manner
that is intuitive to the patient and prac-
titioner is critical if the precision diag-
nosis is to be effective.
Precision Diagnosis in Clinical Practice
Interpreting HbA1c in Diagnosis and
Monitoring
Data and outcomes from thewidespread
useofglycatedhemoglobin (HbA1c), rather
than blood glucose levels, for diagnosis
has led to a precision approach for the
diagnosis of diabetes. The level of HbA1c
will depend on factors that impact
hemoglobin and red cell stability as
well as average glucose values (10).
Genetic testing can reveal unsuspected
variants that alter HbA1c. Thus, knowl-
edge of the patient’s ancestry and
specific genetic information can guide
interpretation of assay results for di-
agnosis and the monitoring of blood
glucose.
Diagnosing T1D Versus T2D
Currently, themost commonstep toward
precisiondiagnosis that ismade in clinical
diabetes medicine is the classification of
T1D versus T2D, the two most prevalent
subcategories with different etiologies
and different treatment requirements.
Part of the diagnostic dilemma is that
neither T1D nor T2D are monolithic
entities and robust “gold standards”
are not universally agreed. Diagnostic
issues arise when expected clinical
features are discordant from established
norms (e.g., people diagnosed with di-
abetes who are young and have obesity,
or old and slim, orwho are a rare subtype
in that clinical setting) (11). Islet auto-
antibody positivity varies by clinical set-
ting (e.g., in people without diabetes,
individuals diagnosed with probable T1D
as children, individuals with clinical fea-
tures of T2D), resulting in an altered prior
probability of T1D that reflects the dif-
ferent prevalence in these diverse set-
tings. The best diagnosis depends on
integrating all diagnostic modalities, as
demonstrated in predicting long term
C-peptide negativity in individuals diag-
nosed with diabetes between 20 and
40 years of age, where an integrated
model outperformed diagnosis based on
clinical features, circulating antibodies,
or genetics used in isolation (3). The
frequency of misdiagnosis of T1D and
Text Box 4—Precision medicine approaches to treat diabetes: background, barriers to implementation, and research gaps
c Type 1 diabetes. The only existing therapy is insulin for T1D. Developments in long-acting and glucose-sensitive insulins are improving the health
andwell-being of people with T1D, as are technological advances in continuous glucosemonitoring devices, insulin pumps, closed-loop systems,
and the artificial pancreas.
c Type 2 diabetes. It has long been recognized that T2D is heterogeneous in its etiology, clinical presentation, and pathogenesis. Yet, traditionally,
trials of therapeutic intervention do not recognize this variation.
c Monogenic formsof diabetes are already amenable to precision treatment, if correctly diagnosed. For example,HNF1A-MODY (MODY3),HNF4A-
MODY (MODY1), and ABCC8-MODY (MODY12) are acutely sensitive to the glucose-lowering effects of sulfonylureas. Alternatively, individuals
with GCK-MODY (MODY2) can have unnecessary treatments stopped.
c With increasing efforts to map patients with T2D in etiological space using clinical andmolecular phenotype, physiology, and genetics, it is likely
that this increasingly granular view of T2D will lead to increasing precision therapeutic paradigms requiring evaluation and potential
implementation.Genetic variationnot only can capture etiological variation (i.e., genetic variants associatedwithdiabetes risk) but also variation
in drug pharmacokinetics (absorption, distribution, metabolism, and excretion [ADME]) and in drug action (pharmacodynamics).
c In contrast, “true” T2D is a common complex disease characterized by thousands of etiological variants, each contributing to a small extent to
diabetes risk. Thus, it remains uncertain that genetic variantswill be identified that are highly predictive of drug outcomes in T2D, even if process-
specific polygenic risk scores are derived (where all variants on an etiological pathway are combined to increase power).
c Barriers to implementation. The current and growing burden of diabetes is not fromwesternwhite populations but fromother ethnic groups, in
particular South and East Asians. Yet, these populations are underrepresented in clinical trials and, in particular, in attempts to understand
variation in drug outcomes.
○ Because the diabetes phenotype can vary markedly by ethnic group, it is likely that complications and drug outcomes will differ between
populations.
○Many of the approaches gaining traction in precisionmedicine generatemassive data sets that are burdensome to store and require powerful
computational servers for analysis.
○Undertaking appropriately designed clinical trials for precision treatments thatmeet the current expectations of regulatory authoritiesmaybe
challenging, given the many subgroups within which treatments will need to be evaluated. Innovative clinical trials will likely be needed and
real-world evidence will likely need to be part of the evaluation process.
○Translating complex information topatients aboutgenetic (andother ’omics) tests in a clear, concise, andclinically relevantmannerwill require
health care providers to be appropriately trained.
c Research gaps. For drug outcomes, there is a pressing need tomove beyond early glycemic response and examine variation in response in terms
of cardiovascular outcomes and mortality rates, especially of the newer agents such as SGLT2i and GLP-1RA, with focus on specific patient
subgroups. Identifying predictive markers (especially genetic markers) of serious adverse events in patients treated with these drugs presents
an additional area urgently in need of greater attention.
○ Need for functional studies to determine the mechanism(s) of action underlying specific gene variants
○ Need for better understanding of the pathophysiology of diabetes to inform on new therapeutic targets
○ Need to study broader populations/ethnic groups
○ Need for understanding outcomes of highest relevance to patients
○ Need for decision-support tools to implement precision diabetes medicine in clinical practice
○ Need to demonstrate that approaches are cost-effective
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T2D in middle-aged and elderly adults
(11,12) suggests that precise diagnostic
approachesareneeded,especiallyas failure
to recognize insulin-deficient states can
be fatal.
Monogenic Diabetes
A Diabetes Care Editors’ Expert Forum
(M.C. Riddle, personal communication)
has concluded recently that amonogenic
diabetes diagnosis is closest to meeting
all criteria for a perfect diagnostic test as
it defines a discrete subgroup giving
insights into etiology, prognosis, and
treatment response (1,2). Most cases
of monogenic diabetes remain misdiag-
nosed. Perhaps the best example of pre-
cision diabetes medicine is the excellent
and long-lasting glycemic response to
oral sulfonylureas in insulin-dependent
infantsdiagnosedwithneonatal diabetes
caused by abnormalities in the b-cell
potassium channel (13–17). In GCK-
MODY (MODY2), it is established that
patients do not require (18), or respond
to, oral medication (19). Other MODY
diagnoses (HNF1A [MODY3], HNF4A
[MODY1] and ABCC8 [MODY12]) are
acutely sensitive to the glucose-lowering
effects of sulfonylureas (20–22); how-
ever, unless thediagnosis is precise, these
therapeutic benefits are lost. With the
clear benefits of precision diagnosis of
monogenic diabetes, it is important to
reduce barriers to its implementation.
For example, the cost of performing
molecular genetic testing is high and
universal testing is not cost-effective. It
is thus necessary to limit testing to those
most likely to have a monogenic diag-
nosis. Moreover, identification proto-
cols require prescreening based on
clinical features (e.g., family history,
age at onset, phenotype including syn-
dromic features) and nongenetic testing
(islet autoantibodies and C-peptide).
One approach for implementing pre-
cisionmedicine in the case of monogenic
diabetes would be to:
c test all infants diagnosed with diabe-
tes in the first 6 months of age, be-
cause .80% have a monogenic cause
of neonatal diabetes;
c use aMODY calculator to identify those
whose clinical features suggest a high
likelihoodofMODY (www.diabetesgenes
.org/mody-probability-calculator/) (23);
c test individuals with pediatric diabetes
when at least three islet autoantibod-
ies are antibody negative (24).
The effective use of these pregenetic
selection criteria should greatly improve
the likelihood of correctly diagnosing
monogenic diabetes without the burden
of costly genetic screens. Although di-
agnostic molecular genetic testing uti-
lizes robust analysis of germline DNA,
which is virtually unchanged throughout
life, there are still issues with its imple-
mentation. One issue is the incorrect
interpretation of the genetic informa-
tion, leading to inaccurate identification
of causal mutations in both clinical prac-
tice and in the published research lit-
erature (25). Curation of pathogenic
variants formonogenicdiabetes is critical
and is currently being addressed by in-
ternational consortia. As a result of tech-
nological advances, multiple causes of
monogenic diabetes canbe tested for in a
single next-generation sequencing test.
This approach is generally advantageous
as it does mean that syndromic mono-
genic diabetes is diagnosed genetically
when the patient presents with isolated
diabetes. Thiswill allow other features to
be examined and treated appropriately
before clinical presentation. Examples of
this are neonatal diabetes (2), HNF1B-
MODY (MODY5) (26), WFS1 (Wolfram
syndrome) (27), and mitochondrial di-
abetes (28). For these patients, the ge-
netic diagnosis of diabetes will have
implications far beyond the prognosis
and care of diabetes, as the patient
Figure 2—Precision diagnostics
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with certain types ofmonogenic diabetes
will also be at high risk of developmental
delay, neurological disease, developmen-
tal kidney disease, liver failure, deafness,
and cardiomyopathy.
Diagnosing Latent Autoimmune Diabetes
in Adults
Latent autoimmune diabetes in adults
(LADA) is not currently recognized by the
ADA as a formal subtype of diabetes.
Nevertheless, LADA reveals some of the
difficulties in diabetes subtyping. It was
shown that the presence of GAD auto-
antibodies in patients with T2D was
associated with progression to early in-
sulin therapy (29); yet, controversy re-
mains as to whether LADA is a discrete
subtype, a milder form of T1D, or a
mixture of some patients with T1D
and others with T2D. The uncertainty
is increased by variation in the diagnostic
criteria, with initial treatment based
upon physician preference as well as
the patient’s presentation (30). In addi-
tion, among those with GAD autoanti-
bodies, the phenotype varies with
different autoantibody levels (31).
Subcategories of Common Forms of
Diabetes
The subcategorization of T1D or T2Dmay
not always be the optimal approach for
precision diabetes diagnosis or therapy.
Nevertheless, the ability to delineate T1D
or T2D using nontraditional data and
approaches may lead to improvements
in prevention or treatment of the dis-
ease, including diabetes subclassifica-
tions beyond T1D or T2D.
Subcategories in T1D.The age at which the
initial islet autoantibody appears and the
type of autoantibody (e.g., which of the
four primary antibodies among islet cell
autoantigen 512/islet antigen 2 [ICA512/
IA-2], insulin, GAD, zinc transporter
8 [ZnT8]) may be important in defining
etiological subtypes of T1D (32). Data
supporting this potential subcategory
are based upon those diagnosed in
the first 10 years of life and in pre-
dominantly white European popula-
tions. The relevance to other ethnic
groups and those diagnosed later in
life is uncertain.
Thegenetic variants accounting for the
majority of risk of T1D are now known,
and the sensitivity and specificity of T1D
genetic risk scores (T1D-GRS) both ex-
ceed 80% (5,33–35); however, a high
T1D-GRSwill have lowpositive predictive
value in populations with a typically low
prevalence. A T1D-GRS may prove most
useful when integrated with clinical fea-
tures and islet autoantibodies (3,4).
There is variation in the genetic suscep-
tibility with age at diagnosis but, at
present, genetics is not suggested as
an approach for defining subtypes of
T1D.
There is strong evidence for enrich-
ment of immune cell types that are
associated with genetic risk of T1D, par-
ticularly T cells (CD41 and CD81) and B
cells (CD191). However, at present, there
is no immune-based test sufficiently re-
producible and robust that it can be used
diagnostically for T1D.
Persistent endogenous b-cell function
in T1D is associated with greater poten-
tial for improved glycemic control and
reduced complications (36). A stimulated
C-peptide measurement represents a
candidate for defining subcategories of
T1D with different treatment aims.
C-peptide levels exponentially fall in
the “honeymoon period” after T1D di-
agnosis (37) but have been shown to be
stable 7 years after diagnosis (38). Per-
sistent C-peptide is associated with a
later age of diagnosis, although there
are few data to predict those likely to
maintain high levels of C-peptide.
Subcategories in T2D. Family history of
T2D, as a surrogate for precise genetic
evaluation, fails to meet many of the
criteria of a robust test as any assessment
changes over time and depends on the
relatives selected for reporting the “fam-
ily.” The value of a family history may be
Figure 3—Precision therapeutics
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greatest in monogenic diabetes, in which
a pedigree will often demonstrate a pat-
ternof inheritanceconsistentwithasingle
gene disorder and a consistent phenotype.
T2D treatment response and disease
progression can be predicted from con-
tinuous clinical features with specific
models. Thesemodels appear to perform
better than dividing into cluster-based
subgroups (7). An advantage of using
clinical features is that they are widely
available and easily obtained (e.g., sex,
BMI, HbA1c). However, they are limited
by the fact that clinical features may vary
over time and with the natural history of
thedisease. Incorporationof longitudinal
change with treatment response could
be a strength as the model’s prediction
would change in concert with changes in
the phenotype of the patient.
Recent research has attempted to de-
fine subcategories of T2D (and T1D)
based on cluster analysis at diagnosis
to provide insights into likely progres-
sion, riskof complications, and treatment
response (39,40). Barriers facing this and
other approaches include collection of
data that are not routinely obtained
(e.g., a fasting C-peptide at the time
of diagnosis, with considerable variation
in results between laboratories [41]) and
the change in biomarkers over time that
are dependent on disease course or its
treatment. Genetic data have been used
todefineT2D subcategories by clustering
genetic variants that associatewith phys-
iological traits and which are correlated
with clinical outcomes (6). At this time,
the available genetic data for T2D and
the clustering does not have sufficient
predictive accuracy to replace existing
delineative approaches. None of the
methods described above are estab-
lished for subclassification of T2D in
clinical practice; nevertheless, it is true
that in a minority of patients, their
specific type of diabetes may be ade-
quately characterized using genetic clus-
tering (42,43).
PRECISION THERAPEUTICS
Accurate diagnosis is necessary for suc-
cessful precision therapy, whether for
prevention or treatment (Fig. 3). This is
truewhere subgroup(s) of thepopulation
must be defined to determine which
targeted interventions will be applied,
aswell as for determination of treatment
outcome. In monogenic diabetes, there
are no currently known options for pre-
vention. In T1D, precision prevention
currently involves mainly the optimiza-
tion of monitoring methods (Text Box 3),
thereby facilitating timely early detec-
tion, preventing early complications
and allowing appropriate treatment. In
contrast, T2D has many avenues for
prevention; thus, the possibilities for
precision approaches, possibly through
tailoring of lifestyle (e.g., diet), are broad
in T2D.
Precision Prevention in Diabetes
(Text Box 3)
Type 1 Diabetes
T1D is characterized by damage, impair-
ment, and eventual destruction of the
insulin-producing pancreatic b-cells,
thought to be the result of an autoim-
mune process. T1D progression has been
grouped into discrete “stages” (44).
Stage 1 is defined by the presence
of $2 islet autoantibodies, with normal
blood glucose; stage 2 is defined by the
presence of$2 islet autoantibodies with
elevation of blood glucose, signaling the
functional impairment of theb-cells; and
stage 3 is characterized by symptoms of
dysglycemia, such as polyuria or diabetic
ketoacidosis, although not all symptoms
need be present. A clinical diagnosis of
T1D typically is not given until stage 3.
T1D is nearly inevitable once $2 islet
autoantibodies appear, particularly in
those of younger age, with a lifetime
diabetes risk approaching 100% (45,46).
Approximately half of the risk of T1D is
due to genetic factors, with over 30% of
Figure 4—Precision prognostics
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the genetic risk attributable to genes of
the human leukocyte antigen (HLA) com-
plex but also includingmore than 50 non-
HLA loci (35). Unknown environmental
factors are thought to trigger the auto-
immune process that results in initial
b-cell damage and progression toward
symptomatic T1D (47).
Primary prevention trials in genetically
susceptible individuals who have not
yet developed autoantibodies (i.e., pre-
stage1)and secondaryprevention trials in
children with stages 1 and 2 have been
conducted (48) using dietary interven-
tions and immune-targeting approaches.
Dietary manipulation studies have been
largely unsuccessful in reducing islet au-
toimmunity (49–51) or T1D (52). Previous
intervention studies among individuals
at stage 1 or stage 2 have been unable
to slow, halt, or reverse the destruction
of insulin-producing b-cells. Of nine
completed secondary prevention trials
(53–60), only one (using an anti-CD3
antibody) has shown a slight delay in
progression to T1D (61).
Most prevention trials in T1D have not
been effective, partially because the
unique T1D genetic risk profile of the
individual and their unique response to
thepreventiveagent (immune therapyor
dietary intervention) have not been con-
sidered. For example, the inflammatory
response to infection with enteroviruses
implicated in the onset of T1D has been
shown to be genetically mediated (62)
and diet has had different effects on
development of autoimmunity and pro-
gression to T1D (63) dependent on
genetic risk. Several studies have sug-
gested that susceptibility to islet auto-
immunity and progression to T1Dmay be
related to the ability to adequately use
vitamin D, as higher cord blood 25-
hydroxyvitamin D was associated with
a decreased risk of T1D, but only in
children who were homozygous for a
vitamin D receptor gene (VDR) variant
(64). Risk of islet autoimmunity was
observed with reduced dietary intake
of the n-3 fatty acid a-linolenic acid, but
only in those with a specific genotype in
the fatty acid desaturase gene (FADS)
cluster (65). Thus, without considering
the unique genetic profiles of children,
dietary supplementation may not be
successful, arguing for an appropriately
validated precision approach.
Type 2 Diabetes
The emergence of T2D as a global public
health crisis during recent decades has
motivated numerous large randomized
controlled trials assessing the efficacy of
pharmacological or lifestyle interven-
tions for prevention. An emphasis has
been placed on intervening in people
with “prediabetes,” defined as a person
with levels of fasting blood glucose, 2-h
blood glucose, or HbA1c that are chron-
ically elevated but below the diagnostic
thresholds for diabetes. Although pre-
diabetes is a major risk factor for T2D
and other diseases (66), intervening in
everyone with prediabetes may not be
cost-effective (67). Aggressive precision
prevention in those with relevant risk
factors is discussed in the current ADA
SOC (68). Youth with prediabetes should be
the focus of preventive interventions, es-
pecially those with overweight or obesity
andwho have one ormore additional risk
factors (e.g., maternal history or exposure
to gestational diabetes mellitus [GDM], a
positive family history of diabetes in first-
or second-degree relatives, signs of insulin
resistance, or specific high-risk ancestry).
Multiple interventions in adults with
T2D have been evaluated for risk reduc-
tion and prevention, both in the short
and the long term. A recent systematic
review (69) reported that after active
interventions lasting from 6 months
to.6years, relativerisk reductionachieved
from lifestyle interventions (39%) was simi-
lar to that attained fromuseof drugs (36%);
however, only lifestyle interventions had a
sustained reduction in risk once the in-
tervention period had ended. Analysis of
the postintervention follow-up period (;7
years) revealed a risk reduction of 28%
with lifestyle modification compared with
a nonsignificant risk reduction of 5%
from drug interventions.
Most lifestyle intervention programs
usestandardizedapproachesdesignedto
change diet and exercise habits for re-
ducing body weight. The Diabetes Pre-
vention Program (DPP) evaluated the
efficacy of lifestyle intervention andmet-
formin therapy, compared with standard
of care and placebo (control), for delay or
prevention of diabetes in those with
impaired glucose regulation at baseline.
Although the reductions in diabetes
risk from lifestyle (58% reduction) and
metformin (31% reduction) compared
Text Box 5—Precision medicine approaches to lessen treatment burden and improve quality of life
c Diagnosis and disease management. A more specific diagnosis has the potential to reduce uncertainty and manage future expectations about
disease course. This is clearly the case for somemonogenic formsof diabetes,wherediagnosis is nearly certain, given its stronggenetic indication,
and the specific treatment is coupled to the subcategory (genetic subtype) of disease. Emerging knowledge regarding subtypes of T2D indicates
that there is potential to classify individuals with diabetes at risk for progression to complications.
c Misdiagnosis. Inaccurate classificationof the type of diabetes, either from lack of precisionor inadequate clinical attention to detail at the timeof
presentation, can have long-lasting, adverse effects onmental health and quality of life. In the pediatric and younger adult population, the risk of
misclassification is increasing as both “true” T1Dand “true” T2D classifications are confused through the growing obesity epidemic in youth (T2D)
and older ages at onset (T1D). In addition, monogenic variants of diabetes can be misdiagnosed as either T1D or T2D. A precision approach to
diagnosis with appropriate standardized laboratory support and increased research to obtain novel biomarkers of disease has the potential to
solve this problem.
c Complications.Worry about complications is an issue for all people with diabetes. Currently, people with diabetes (either T1D or T2D) are given
a label of being unequivocally at risk for reduced life span, amputation, kidney failure, and blindness. A more precise diagnosis, prognosis, and
strategy to predict and prevent complications has the potential to greatly reduce disease burden and distress and improve quality of life.
Nevertheless, there is also a risk that more precise prognostification may cause distress if the options for successful intervention are limited or
incompatible with the patient’s needs or desires.
c Stigmatization.Amajor burden for peoplewith diabetes is that the disease is often considered the fault of the patient. This is particularly true for
T2D, as it is often labeled as “just” a lifestyle disease. Clinical care of those with diabetes often results in a singular approach to treatment,
regardless of their specific needs, life situation, and other conditions. A clinical process thatmakes diagnosismore precise and includes a patient-
oriented evaluation and response to needs has the potential to lessen stigma and reduce associated distress.
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with the control intervention were im-
pressive (70), there was considerable
variation across the study population
(71), with many participants developing
T2D during the active intervention period
(the first 2.8 years of the trial). Thus, the
DPP lifestyle intervention did not truly
“prevent” diabetes. Indeed, in the de-
cade after randomization, during which
participants were offered lifestyle rein-
forcement semiannually, the average
duration before disease onset was ;3
years (72). Those participants in the DPP
who progressed most rapidly were those
who lost the least weight in the early
stages of the intervention (73), with
genetic variants representing significant
predictors of peakweight loss andweight
loss maintenance (74). Results from the
DPP and other large prevention trials
suggest that a “one-size-fits-all” lifestyle
intervention strategy will not be effica-
cious for everyone, particularly if it can-
not be sustained, strengthening the case
for precision lifestyle interventions in
T2D prevention.
Although precision diabetes medicine
is muchmore than genetics, themajority
of relevant research has focused on
evaluating the role of genetic variants
in precision prevention. Large epidemi-
ological studies (75) and intervention
trials (76,77) strongly suggest that stan-
dard approaches for lifestyle modifica-
tion are equally efficacious in preventing
diabetes regardless of the underlying
genetic risk. This contrasts with the
extensive epidemiological evidence sug-
gesting that the relationship of lifestyle
with obesity is dependent on genetic risk
(78–81); however, with few exceptions
(e.g., [74]), analyses in large randomized
controlled trials have failed to show that
these same genetic variants modify
weight loss in response to lifestyle in-
tervention (82). It is also important to
recognize that knowledge of increased
genetic risk for diabetes may not moti-
vate improvements in lifestyle behaviors.
Indeed, knowledge of increased genetic
risk for diabetes may decrease motiva-
tion to modify behavior in genetic fatal-
ists (83).
Diet recommendations optimized to
the individual have been shown to re-
duce postprandial glycemic excursions
to a greater extent than standard
approaches in healthy individuals (84).
Meal compositions that induce the most
favorable glycemic profiles have been
guided by models derived from an indi-
vidual’s biological data (e.g., microbiome,
genome, and metabolome), information
on lifestyle factors (e.g., sleep and exer-
cise), and postprandial glycemia following
the consumption of a series of standard-
ized meals. Although these studies indi-
cate that personalized diet plansmay help
minimize postprandial glycemic excur-
sions, no studies have reported the
long-term impact of adhering to person-
alized diets on glycemic control.
Of the 12 approved classes of diabetes
drugs, many having been assessed for
efficacy in prevention. Overall, drugs that
enhance insulin action haveprovenmore
effective in diabetes prevention than
those that increase insulin secretion.
Some of the variability in the diabetes-
reducing effect of metformin in the DPP
has been associated with variation in the
SLC47A1 gene that encodes the multi-
drug and toxin extrusion 1 (MATE1)
transporter protein (85). In the DPP Out-
comes Study, the effects of lifestyle,
metformin, and placebo interventions
on weight reduction during the 6–15
Figure 5—The path to precision diabetes medicine. HEA, health economic assessment. Adapted from Fitipaldi et al. (136).
care.diabetesjournals.org Chung and Associates 1627
years that followed the end of the
randomized intervention phase were
assessed (86). As a percentage of base-
lineweight, those assigned tometformin
maintained an average weight loss of
6.2% compared with the lifestyle inter-
vention group, which maintained a
weight loss of 3.7%, and the placebo
group, which maintained a weight loss
of 2.8%. In the subgroup of DPP partic-
ipants who lost ,5% baseline weight at
1 year post-randomization (poor res-
ponders), bodyweight during the follow-
ing 14 years remained essentially unchanged,
whether receiving metformin or placebo
interventions. In contrast, those partic-
ipants in the lifestyle intervention group
who lost ,5% baseline weight gained
and sustained;2 kg excess body weight
in the years that followed. These findings
reveal a subgroup of DPP participants
in whom lifestyle intervention led to
weight gain, which presents a potential
avenue for stratified intervention, where
individuals who are unlikely to respond
well to lifestyle modification might be
better served by other therapeutic
approaches.
Precision Treatment (Text Box 4)
Once diabetes develops, a variety of
therapeutic steps may be clinically in-
dicated to improve disease manage-
ment. These steps include:
c glucose monitoring
c patient education and lifestyle inter-
vention (87)
c surgery
c drug treatments to lower HbA1c
c drug treatments to lower cardiovascu-
lar risk (e.g., statins, antihypertensives)
c drug treatments targeting specific
complications (e.g., ACE inhibitors/angio-
tensin II receptor blockers [ARBs] and
sodium–glucose cotransporter 2 [SGLT2]
inhibitors for proteinuric kidney disease,
fibrates for retinopathy, atypical analge-
sics for painful neuropathy, and statins
and antihypertensives for cardiovascular
disease)
For each of these treatments, there
will be patients who respond well and
those who respond less well, in addition
to those who have adverse outcomes
fromthe therapy. Thus, precision treatment
can be considered as using patient char-
acteristics to guide the choice of an
efficacious therapy to achieve the
desired therapeutic goal or outcome
while reducing unnecessary side ef-
fects (Fig. 3). Given the broad scope
of precision treatment, pharmacolog-
ical therapy in T2D has the best evi-
dence base for precision therapeutics
at present.
Subcategories and Drug Outcomes
Traditionally, trials of therapeutic inter-
ventions do not recognize variation in
etiologic processes that lead to develop-
ment of T2D. The MASTERMIND consor-
tium recently reanalyzed data from the
A Diabetes Outcome Progression Trial
(ADOPT) and Rosiglitazone Evaluated
for Cardiac Outcomes and Regulation
of Glycaemia in Diabetes (RECORD)
studies in order to highlight how clin-
ical phenotype can be used to help
guide treatment intervention. In ADOPT,
on average, men without obesity showed
a greater HbA1c reduction over 5 years
with sulfonylureas than they did with
thiazolidinediones; however, womenwith
obesity treated with thiazolidinediones
had sustained HbA1c lowering over the
5 years compared with sulfonylureas
(88). When considering the clinical and
physiological variables used to subgroup
individuals with diabetes (39), the in-
sulin-resistant cluster defined in ADOPT
and RECORD responded better to thia-
zolidinediones while the older patient
cluster responded better to sulfonyl-
ureas (7).
Similar studies have been undertaken
to investigate how simple clinical varia-
bles can be used to predict glycemic
response to dipeptidyl peptidase 4 inhib-
itors (DPP4i). In studies undertaken using
prospective (Predicting Response to In-
cretin Based Agents in Type 2 Diabetes
study [PRIBA]) and primary care data in
the U.K. (Clinical Practice Research Data-
link [CPRD]), an insulin-resistant pheno-
type of obesity and high triacylglycerols
was associated with reduced initial re-
sponse toDPP4i andmore rapid failure of
therapy (89).
As outlined under PRECISION DIAGNOSTICS
and elsewhere (the upcoming Expert
Forum), the most current examples of
how genetics impacts precision treat-
ment can be seen in monogenic diabe-
tes, for which single gene mutations are
causal for the development of diabetes
and for which targeted treatments can,
in effect, bypass the etiological defect
(e.g., sulfonylurea sensitivity in HNF1A-
MODY [MODY3] [20] and insulin inde-
pendence with high-dose sulfonylureas
in neonatal diabetes due to KATP channel
defects [14]). In some instances, pre-
cision treatment may result in cessa-
tion of unnecessary medication, as is
the case in people with GCK-MODY
(MODY2), where blood glucose remains
somewhat elevated, but stable, over
time.
Unlike monogenic forms of diabetes,
T2D is a common complex disease char-
acterized by thousands of etiological
gene variants. It is uncertain whether
individual genetic variants will be highly
predictive of drug outcomes. Similar to
the underlying genetic architecture of
T2D, it is possible that drug response in
T2D will be influenced by many genetic
variants of small to modest effect. Ge-
netic studies of drug response in T2D
have largely been based on candidate
genes of known etiological processes or
drug pathways. These studies have been
limited in their success. For example,
some studies have shown that the
KCNJ11/ABCC8 E23K/S119A risk variant
increases glycemic response to sulfony-
lureas (90–92); in contrast, the TCF7L2
diabetes risk variant reduces glycemic
response to sulfonylureas (93–95). The
PPARG Pro12Ala diabetes risk variant
has been associated with reduced gly-
cemic response to thiazolidinediones
(96–98).
Genome-wide association studies
(GWAS) have the potential to provide
novel insights as they make no assump-
tions about drug mechanism or disease
process, in contrast to candidate gene/
pathway studies. Only GWAS of metfor-
min have been reported to date (99,100),
identifying that variants at the ATM/
NPAT and SLC2A2 loci are associated
with an altered glycemic response. In
SLC2A2, the noncoding rs8192675 vari-
ant C allele is associated with greater
response to metformin and is associated
with reduced expression of the SLC2A2
transporter in liver, intestines, and kid-
neys. In individuals with obesity, those
with two copies of the C allele had an
absolute HbA1c reduction of ;1.55%
(compared with a reduction of ;1.1%
in those without the C allele). While this
may appear to be a small difference, the
SLC2A2 genotype effect is the equivalent
of a difference in metformin dose of
550 mg, or about half the average effect
of starting a DPP4i.
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When considering etiological varia-
tion, recent work partitioning diabe-
tes-associated genetic variants by their
presumed etiological process (parti-
tioned polygenic scores) (6,42,101)
may define genetically driven dominant
processes. These processes, such as
b-cell dysfunction, lipodystrophy, orobe-
sity, could respond differently to drugs
that act on these pathways, such as
sulfonylureas, glucagon-like peptide1 re-
ceptor agonist (GLP-1RA), DPP4i, and
thiazolidinediones.
Genetic variation can not only capture
etiological variation but also variation in
drug pharmacokinetics (absorption, dis-
tribution, metabolism, excretion [ADME])
and in drug action (pharmacodynamics).
Studies of ADME genes have revealed
some variants with a moderate to large
effect. For example, the 8% of the white
population who carry two loss-of-function
variants in CYP2C9 are 3.4 times more
likely to achieve HbA1c target than those
with normal function cytochrome P450
family 2 subfamily C member 9 (CYP2C9)
due to reduced metabolism of sulfonyl-
ureas and increased serum concentrations
(102). SLCO1B1 and CYP2C8 genotypes
that alter liver uptake andmetabolism of
rosiglitazone can alter glycemic response
(HbA1c) by as much as 0.7% (103). While
these studies have promoted pharmaco-
genetic approaches in precision diabetes
therapeutics, some studies have been
surprisingly negative. For example, loss-
of-function variants in the SLC22A1 gene,
encoding the organic cation transporter
1 (OCT1), which transports metformin
into the liver (104,105), donot reduce the
glucose-lowering efficacy of metformin
in patients with T2D (106,107). Thus,
there is genetic evidence that metformin
does not work to lower glucose solely via
hepatic mechanisms.
The diabetes phenotype is markedly
different across ethnic groups; thus, it is
likely that drug outcomes will differ
between populations. The current and
growing burden of diabetes is growing
rapidly in all populations, particularly in
South and East Asians, yet these pop-
ulations are underrepresented in clinical
and drug outcomes trials. A lack of
systematic reviews and meta-analyses
from these high-prevalence regions still
points to differences in drug response.
For example, the DPP4i response is
greater in Asian than white people
(108), a result supported by a subgroup
analysis of the Trial Evaluating Cardio-
vascular Outcomes with Sitagliptin (TE-
COS) showing a greater HbA1c reduction
to sitagliptin in East Asians compared
with white individuals (109). Glycemic
response to metformin has also been
reported to differ by ethnic group, with
African American individuals having a
greater response than European Amer-
icans (110).
At this time, it is evident that we have
the potential to use simple clinical (e.g.,
BMI, sex, ethnicity), physiological, and
genetic variables to predict who is more
or less likely to benefit from a treatment.
The reducing costs of genotyping panels
mean that genotype information could
potentially be available at the point of
prescribing, when the modest effect sizes
describedmay start to have clinical utility.
There is a need to develop implementa-
tion and evaluation strategies to assess
the effectiveness and cost-effectiveness




In women, being affected by GDM is a
major risk factor for T2D. The risk of
developing T2D in women with prior
GDM approaches 70% after the index
pregnancy (111), climbing to an 84% risk
of developing T2D in women of East
Indian ancestry (112). Currently, genetic
studies of GDM have identified those
variants known to increase risk of T2D
(113); however, other variants have been
shown to influence glycemic traits spe-
cifically inpregnancy (114). Furthermore,
like T2D, GDM is a heterogeneous con-
dition linked to primary defects in either
insulin secretion or sensitivity (115,116).
GDM can also result from monogenic
forms of diabetes, as numerous studies
have shown. Models that attempt to
predict pregnancy complications (117)
or subsequent T2D (118) in GDM using
clinical characteristics, biomarkers, and/
or genetic variants have yet to be adopted,
even though both lifestyle interventions
and metformin use have demonstrated
benefits in reducing the risk of T2D in
women with prior GDM (119).
The target for all patients with T1D or
T2D in pregnancy is to achieve as near
normal glucose as possible, particularly
around the timeof conception (to reduce
developmental anomalies) and in the
third trimester (to reduce the risk of
macrosomia) (120). In pregnancy, the
only clear exception so far is for mothers
withGCK-MODY (MODY2) as fetal growth
is determined predominantly by fetal
genotype (121). In mothers whose fetus
inherits the mother’s GCK-MODY muta-
tion, fetal growth is normal despite the
maternal hyperglycemia; thus, treatment
of the maternal hyperglycemia is not
recommended (121,122). Establishing
whether the fetus is likely to be affected
is usually determinedbyultrasound scan.
In the future, the use of noninvasive cell-
free DNA methods in maternal blood
will likely establish fetal risk (123). In
GDM, whether maternal hyperglycemia
is closely monitored and treated in the
third trimester is based on the degree of
hyperglycemia determined by an oral
glucose tolerance test at 24–28 weeks’
gestation (10). In the future, this decision
could be modified by nonglycemic factors




Precision diabetes medicine holds the
promise of reducing uncertainty by pro-
viding therapies that are more effective,
less burdensome, andwith fewer adverse
outcomes, which ultimately improve qual-
ity of life and reduce premature death (see
Text Box 5). Highly relevant in this context
is mental health (e.g., risk of distress and
depression), yet little has been done to
investigate how precision medicine might
play a useful role in improving mental
health outcomes.
Depression and anxiety are twice as
common in people with diabetes than in
the general population, occurring in up
to 20% of adult patients (124). Distress
occurs in ;30% of people with diabetes
(125) reflecting the emotional and psy-
chological burden that comes with di-
abetes and its complications, the life
adjustments it requires, and anxiety
about hypoglycemia or the impact on
the fetus for GDM. Distress has been
reported as being more common in
patients in secondary rather than pri-
mary care and in populations with non-
European ancestry. Depression is more
common in lower- and middle-income
countries, where ;75% of people with
T2D reside (125). Both depression and
distress in diabetes are more common in
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those who progress from oral agents to
insulin therapy (126). The onset of com-
plications with the initiation of a more
complexpatternof treatment is associated
with increased rates of depression (126).
There are key points in the life course
of a person with diabetes when both
rational and irrational fears are often
elevated, typically coinciding with “events,”
including:
c increased medication dose
c transition to insulin or other injectables
or devices
c emergence of complications or wors-
ening of complications
c following a severe hypoglycemic event
c change in diabetes care provider.
Inmany cases, patient self-evaluations
may be distorted at these times because
the patient attributes blame for the
disease to themself, the future feels
uncertain and distress peaks. In the
setting of precision diabetes medicine,
providers should assess symptoms of
diabetes distress, depression, anxiety,
disordered eating, and cognitive capaci-
ties using appropriate standardized and
validated tools at the initial visit, at
periodic intervals, and when there is a
change in disease, treatment, or life
circumstance (127), information that,
when combined with other data, are
likely to improve the precision of clinical
decision making.
Psychological counseling can help pa-
tients understand and manage their
emotional reactions to major events
by developing a more optimistic outlook
andmore realistic,modulated, and adap-
tive emotional reactions (128). Precision
medicine may be used in the future to
help predict the frequency and extent of
emotional crises. As a result, precision
diabetes medicine may lessen the patient
burden, help patients to objectivize their
disease, and provide targets for behav-
ioral and point-of-care interventions at
criticalmoments in the clinical care cycle.
Effective and tailored education and pro-
fessional counseling will be necessary to
mitigate the risk that a clearer prognosis
may raise anxiety about the future for
some patients.
EQUITY IN PRECISION DIABETES
MEDICINE
Theexperiencewithmonogenic diabetes
has shown that there is a large degree of
regional, national, and international var-
iation in how, and howoften, these cases
are diagnosed (1,129,130). This variation
is, in part, due to differences in access to
general medical care and treatments,
access to relevant health care professio-
nals with the necessary education, tra-
ining, and experience, and access to
laboratories with the necessary experi-
ence, assays, and standards (131). A
precision approach to diabetes care
will require that the relevant laboratory
methods and assays are carefully stan-
dardized and comparable. Assessments
that need to be standardized include:
c T1D-associated autoantibodies
c C-peptide
c clinical genetic/genomic risk scores
c decision-support interpretation.
A challenge is that the frequency of
various diabetes phenotypes and risk
genotypes may vary by regions of the
world and between ethnicities within a
region. For example, T2Doftenmanifests
very differently in Native Americans than
in people of European ancestry, with
Native Americans tending to develop
diabetes at a much younger age and
experience loss of b-cell function earlier
in the life course of the disease (132).
Recent insights following the ADA Pre-
cision Diabetes Medicine meeting in
Madrid (held in October 2019) confirm
that case-based interactive learning is an
excellent way to support this type of
postgraduate education for clinicians at
all levels of training.
THE ROAD TO IMPLEMENTATION
Advances in science allow for generation
of large-scale biological and physiological
data that can be harnessed for precision
diagnostic (Fig. 2), therapeutic (Fig. 3),
and prognostic (Fig. 4) purposes. Pro-
grams are needed to train, foster, and
retain individuals with biological and
data science expertise who will contrib-
ute to precision diabetes medicine ef-
forts. Furthermore, clinicians, scientists,
and regulators must collaborate to de-
velop standards and safeguards for pro-
tecting the accumulated “precise” data,
which in some instances may lead to
unintended and sensitive revelations, on
individuals in a secure manner across
populations and across countries.World-
wide differences in prevalence of the
forms of diabetes necessitates inclusion
of currently understudied populations
for the development of precision diag-
nostics and therapeutics. As a result, the
precise subtype of diabetes a particular
individual is diagnosed with may vary in
different populations based on subtype
frequency or genetic or dietary or life-
style differences.
The communication strategy used by
the interventionalist and the patient’s
perception of risk may be important
factors contributing to the successful
implementation of precision diabetes
medicine. Both personal and societal
barriersmay exist to the implementation
of precision prevention across geo-
graphic regions and countries. Discus-
sions with global and regional regulatory
agencieswill be needed todetermine the
level of evidence needed for approval
and adoption of precision diagnostics
and therapeutics. The development of
tools and strategies to synthesize patient
data and facilitate shared decision mak-
ing will be needed to translate evidence
for precision diabetes medicine into in-
dividualized diabetes care, accounting
for patient preferences and behaviors,
health literacy, and socioeconomic con-
siderations. Pragmatic studiesofdecision-
support systems utilizing rich information
in these health care systems, particularly
those with biobank-linked electronic
health care records, are needed to guide
implementation of precision diabetes
medicine into clinical practice and to
generate the much needed cost-efficacy
data for broader adoption.
BUILDING PARTNERSHIPS
Partnerships must be established be-
tween the scientific community, pa-
tients, health care systems, providers,
payors, industry, and regulatory bodies
involved in the development, evaluation,
approval, adoption, and implementation
of precision diagnostics, monitoring, and
therapeutics that aredeemedacceptable
for safe, efficacious, and cost-effective
use in precision diabetes care. Making
the most of the opportunities offered by
precision diabetes medicine will require
many different stakeholders to form
highly effective partnerships. Without
networks of partnerships that span aca-
demic institutions, corporations, payors,
regulators, andmedical and public interest
groups with shared understanding and
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vision (Fig. 5), precision diabetes medi-
cine is destined to fail. Partners inmaking
precision diabetes medicine a reality
include:
People with diabetes. People with di-
abetes are the most important sta-
keholders. In Western countries,
between 1 in 10 and 1 in 20 people
have diabetes, while in other parts of
the world, diabetes is more prevalent
(1 in 3 in some Middle Eastern popula-
tions (133), and 1 in 2 in some Native
American tribes [132]). The precision
approach to diabetes will require effec-
tive patient-facing, bidirectional commu-
nication strategies that explain what
precision medicine is and how it works.
People with diabetes should be invited
to contribute to research through advisory
and advocacy positions, to contribute to
postgraduate educational programs for
clinicians and to play a central role in
discussions with politicians, regulators,
and payors.
Regulatory agencies. The transition
from current diabetes clinical practice
to a precision medicine approach will
have important implications for the de-
velopment, prescription, and regulation
of diagnostics and therapeutics. Involve-
ment of regulators at the earliest stages
of the precision diabetes medicine work-
flow will be critical to the successful
implementation of the precision ap-
proach. Recognizing these challenges,
the FDA and the European Medicines
Agency have initiated discussions relat-
ing to standards for evidence and the
design of future clinical trials for pre-
cision diabetes medicine (134).
Payors. Payment for medical care re-
lated to diabetes varies greatly, includ-
ing between regions within countries,
with costs for diabetes often hidden in
other areas of medical care. Fragmenta-
tion of sites of delivery for diabetes care
and its costs directly impact payment
policies. There is evidence in the case of
monogenic diabetes that a precision
medicine approach is cost-effective
(135). The delay, or prevention, of com-
plications (the major contributor to di-
abetes costs) through precision diabetes
medicine may be the strongest driver for
adoption.
Product manufacturers. Diabetes
technology, including the development
of wearable devices for glucose mo-
nitoring and for regulating insulin infu-
sions (i.e., the artificial pancreas), has
developed rapidly and is an example
of widespread personalized diabetes
medicine. Technology and pharmaceu-
tical implementation is currently at a
pre-precision level, and treatment
guidelines are quite generic. The Euro-
pean Federation of Pharmaceutical
Industries and Associations (EFPIA) Di-
abetes Platform, in which six leading
pharmaceutical companies are develop-
ing shared policy goals focused on im-
proving diabetes clinical outcomes, has
initiated multiple projects with strong
precision diabetes medicine agendas,
with other public-private partnerships
focused on precision diabetes medicine
underway (136).
Private and public supporters of re-
search. Support for diabetes research
funding has struggled as its priority
has fallen among the general public
and some political decision makers,
where cancer and cardiovascular disease
rank consistently higher thandiabetes on
the public agenda. For precision diabetes
medicine to meaningfully improve the
lives of patients, it will be necessary to
build highly effective networks of key
stakeholders, such that common agen-
das are agreed to and funding for re-
search and implementation is made
available. This, in turn, requires that
the evidence justifying a precision di-
abetes medicine approach is clearly ar-
ticulated to all major decision makers,
including funders.
Clinicians and professional organiza-
tions. Medical care for the person with
diabetes involves a wide spectrum of
health care providers, including tertiary
and secondary specialists, general intern-
ists, primary care doctors, nurses, die-
titians, podiatrists, pharmacists, and
other paramedical professionals. Several
organizations are engaged in the PMDI
(ADA, EASD,NIDDK) and representatives
of professional bodies in Asia, Africa, and
elsewhere are being engaged by the
PMDI to ensure global impact. Tailoring
educational modules and content to
different professional and cultural set-
tings is ideally suited to these partner
organizations.
General public. The enormous burden
that diabetes places on many health
care systems is usually shouldered by
the general public, owing to the high
costs of treating the disease and loss of
public revenue through decreased pro-
ductivity. The effective implementation
of precision prevention will require
that the general public embraces the
approach and that those in greatest need
can access precision prevention programs.
Diabetes messaging for the general public
can be modeled on precision oncology,
for which public advocacy and engage-
ment have been successful, effectively
utilizing social media as well as traditional
media to communicate not only its




Precision diabetes medicine has found a
firm foothold in the diagnosis and treat-
ment of monogenic diabetes, while the
application of precision medicine to
other types of diabetes is at this time
aspirational, rather than standard of
care. The ability to integrate the diag-
nosis ofmonogenic diabetes into routine
clinical care is one example where diag-
nostics are essential and meet many of
the characteristics of the ideal test. De-
spite an excellent diagnostic paradigm,
there are no known avenues for pre-
vention inmonogenic diabetes, although
careful monitoring in presymptomatic
variant carriers may lead to early de-
tection of diabetes and rapid treatment.
Future precision diabetes medicine
approaches are likely to include diagnos-
tic algorithms for defining diabetes
subtypes in order to decide the best
interventional and therapeutic ap-
proaches. The scope and potential for
precision treatment in diabetes is vast,
yet deep understanding is lacking. It will
be imperative to determine when and
how the application of therapeutics in
precision diabetes medicine improves
outcomes in a cost-effective fashion.
There are many important stakehold-
ers whose engagement will be necessary
for the implementation of precision di-
abetes medicine to succeed (Fig. 5).
Progress in translating advances in bio-
logy and technology will be governed by
the identification, accurate measure-
ment, and scalable deployment of agents
for diagnosis and therapy, so broad
stakeholder engagement is essential. It
is crucial that precision approaches are
available to the full diversity of human
populations and societal contexts, such
that precision diabetes medicine does
not widen health disparity but achieves
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the greatest benefits to all individuals
and society as a whole. Highly functional
partnerships with patient representa-
tives and public organizations will be
required to reap the benefits of precision
diabetes medicine.
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Association between TCF7L2 genotype and gly-
cemic control in diabetic patients treated with
gliclazide. Int J Endocrinol 2013;2013:374858
96. Kang ES, Park SY, Kim HJ, et al. Effects of
Pro12Ala polymorphism of peroxisome prolifer-
ator-activated receptor gamma2 gene on rosi-
glitazone response in type 2 diabetes. Clin
Pharmacol Ther 2005;78:202–208
97. Hsieh MC, Lin KD, Tien KJ, et al. Common
polymorphisms of the peroxisome proliferator-
activated receptor-gamma (Pro12Ala) and per-
oxisome proliferator-activated receptor-gamma
coactivator-1 (Gly482Ser) and the response to
pioglitazone in Chinese patients with type 2
diabetes mellitus. Metabolism 2010;59:1139–
1144
98. Pei Q, Huang Q, Yang GP, et al. PPAR-g2 and
PTPRD gene polymorphisms influence type 2
diabetes patients’ response to pioglitazone in
China. Acta Pharmacol Sin 2013;34:255–261
99. Zhou K, Bellenguez C, Spencer CC, et al.;
GoDARTS and UKPDS Diabetes Pharmacoge-
netics StudyGroup;WellcomeTrust CaseControl
Consortium 2; MAGIC investigators. Common
variants near ATM are associated with glycemic
response to metformin in type 2 diabetes. Nat
Genet 2011;43:117–120
100. Zhou K, Yee SW, Seiser EL, et al.; MetGen
Investigators; DPP Investigators; ACCORD Inves-
tigators. Variation in the glucose transporter gene
SLC2A2 is associated with glycemic response to
metformin. Nat Genet 2016;48:1055–1059
101. Mahajan A, TaliunD, ThurnerM, et al. Fine-
mapping type 2 diabetes loci to single-variant
resolution using high-density imputation and
islet-specific epigenome maps. Nat Genet 2018;
50:1505–1513
102. Zhou K, Donnelly L, Burch L, et al. Loss-of-
function CYP2C9 variants improve therapeutic
response to sulfonylureas in type 2 diabetes:
a Go-DARTS study. Clin Pharmacol Ther 2010;87:
52–56
103. Dawed AY, Donnelly L, Tavendale R, et al.
CYP2C8 and SLCO1B1 variants and therapeutic
response to thiazolidinediones in patients with
type 2 diabetes. Diabetes Care 2016;39:1902–
1908
104. Shu Y, Sheardown SA, Brown C, et al. Effect
of genetic variation in the organic cation trans-
porter 1 (OCT1)onmetforminaction. J Clin Invest
2007;117:1422–1431
105. Sundelin E, Gormsen LC, Jensen JB, et al.
Genetic polymorphisms in organic cation trans-
porter 1attenuateshepaticmetforminexposure in
humans. Clin Pharmacol Ther 2017;102:841–848
106. Zhou K, Donnelly LA, Kimber CH, et al.
Reduced-function SLC22A1 polymorphisms en-
coding organic cation transporter 1 and glycemic
response to metformin: a GoDARTS study. Di-
abetes 2009;58:1434–1439
107. Dujic T, Zhou K, Yee SW, et al. Variants in
pharmacokinetic transporters and glycemic re-
sponse to metformin: a MetGen meta-Analysis.
Clin Pharmacol Ther 2017;101:763–772
108. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS,
Cho YM. Differences in the glucose-lowering
efficacy of dipeptidyl peptidase-4 inhibitors be-
tween Asians and non-Asians: a systematic re-
view and meta-analysis. Diabetologia 2013;56:
696–708
109. Davis TME, Mulder H, Lokhnygina Y, et al.;
TECOS Study Group. Effect of race on the gly-
caemic response to sitagliptin: insights from the
Trial Evaluating Cardiovascular Outcomes with
Sitagliptin (TECOS). Diabetes Obes Metab 2018;
20:1427–1434
110. Williams LK, PadhukasahasramB, Ahmedani
BK, et al. Differing effects of metformin on
glycemic control by race-ethnicity. J Clin En-
docrinol Metab 2014;99:3160–3168
111. Kim C, Newton KM, Knopp RH. Gestational
diabetes and the incidence of type 2 diabetes:
a systematic review. Diabetes Care 2002;25:
1862–1868
112. Das Gupta R, Gupta S, Das A, Biswas T,
Haider MR, Sarker M. Ethnic predisposition of
diabetes mellitus in the patients with previous
history of gestational diabetesmellitus: a review.
Expert Rev Endocrinol Metab 2018;13:149–158
113. LoweWL Jr, Scholtens DM, Sandler V, Hayes
MG. Genetics of gestational diabetes mellitus and
maternal metabolism. Curr Diab Rep 2016;16:15
1634 Consensus Report Diabetes Care Volume 43, July 2020
114. Hayes MG, Urbanek M, Hivert MF, et al.;
HAPO Study Cooperative Research Group. Iden-
tification of HKDC1 and BACE2 as genes influ-
encing glycemic traits during pregnancy through
genome-wide association studies. Diabetes
2013;62:3282–3291
115. Powe CE, Allard C, Battista MC, et al.
Heterogeneous contribution of insulin sensitivity
and secretion defects to gestational diabetes
mellitus. Diabetes Care 2016;39:1052–1055
116. Benhalima K, Van Crombrugge P,Moyson C,
et al. Characteristics and pregnancy outcomes
across gestational diabetes mellitus subtypes
based on insulin resistance. Diabetologia 2019;
62:2118–2128
117. CooraySD,Boyle JA, SoldatosG,Wijeyaratne
LA, Teede HJ. Prognostic prediction models for
pregnancy complications in women with gesta-
tional diabetes: a protocol for systematic review,
critical appraisal and meta-analysis. Syst Rev
2019;8:270
118. Tobias DK. Prediction and prevention of
type 2 diabetes in womenwith a history of GDM.
Curr Diab Rep 2018;18:78
119. Aroda VR, Christophi CA, Edelstein SL,
et al.; Diabetes Prevention Program Research
Group. The effect of lifestyle intervention and
metformin on preventing or delaying diabetes
among women with and without gestational
diabetes: the Diabetes Prevention Program out-
comes study 10-year follow-up. J Clin Endocrinol
Metab 2015;100:1646–1653
120. American Diabetes Association. 14. Man-
agement of diabetes in pregnancy: Standards of
Medical Care in Diabetesd2020. Diabetes Care
2020;43(Suppl. 1):S183–S192
121. SpyerG,MacleodKM,ShepherdM,EllardS,
Hattersley AT. Pregnancy outcome in patients
with raised blood glucose due to a heterozygous
glucokinasegenemutation.DiabetMed2009;26:
14–18
122. Sanyoura M, Letourneau L, Knight
Johnson AE, et al. GCK-MODY in the US mono-
genic diabetes registry: description of 27 un-
published variants. Diabetes Res Clin Pract
2019;151:231–236
123. DeFrancoE, Caswell R, Houghton JA, Iotova
V, Hattersley AT, Ellard S. Analysis of cell-free
fetal DNA for non-invasive prenatal diagnosis in
a family with neonatal diabetes. Diabet Med
2017;34:582–585
124. Petrak F, Baumeister H, Skinner TC, Brown
A, Holt RIG. Depression and diabetes: treatment
and health-care delivery. Lancet Diabetes Endo-
crinol 2015;3:472–485
125. Snoek FJ, Bremmer MA, Hermanns N.
Constructsofdepressionanddistress indiabetes:
time for an appraisal. Lancet Diabetes Endocrinol
2015;3:450–460
126. Moulton CD, Pickup JC, Ismail K. The link
between depression and diabetes: the search for
shared mechanisms. Lancet Diabetes Endocrinol
2015;3:461–471
127. American Diabetes Association. 5. Facili-
tating behavior change and well-being to im-
prove health outcomes: Standards of Medical
Care in Diabetesd2020. Diabetes Care 2020;
43(Suppl. 1):S48–S65
128. Fisher L, Polonsky WH, Hessler D. Ad-
dressing diabetes distress in clinical care:
a practical guide. Diabet Med 2019;36:803–
812
129. Shields BM, Hicks S, Shepherd MH,
Colclough K, Hattersley AT, Ellard S. Maturity-
onset diabetes of the young (MODY): how many
cases are we missing? Diabetologia 2010;53:
2504–2508
130. ShepherdM,ColcloughK,EllardS,Hattersley
AT. Ten years of the national genetic diabetes
nurse network: a model for the translation of
genetic information into clinical care. Clin Med
(Lond) 2014;14:117–121
131. Owen KR. Monogenic diabetes in adults:
what are the new developments? Curr Opin
Genet Dev 2018;50:103–110
132. Poudel A, Zhou JY, Story D, Li L. Diabetes
and associated cardiovascular complications in
American Indians/Alaskan Natives: a review of
risks and prevention strategies. J Diabetes Res
2018;2018:2742565
133. Al Busaidi N, Shanmugam P, Manoharan D.
Diabetes in the Middle East: government health
care policies and strategies that address the
growing diabetes prevalence in the Middle
East. Curr Diab Rep 2019;19:8
134. Meyer RJ. Precision medicine, diabetes,
and the U.S. Food and Drug Administration.
Diabetes Care 2016;39:1874–1878
135. Naylor R. Economics of genetic testing for
diabetes. Curr Diab Rep 2019;19:23
136. Fitipaldi H, McCarthy MI, Florez JC,
Franks PW. A global overview of precision
medicine in type 2 diabetes. Diabetes 2018;
67:1911–1922
137. O’Brien RL, Brinster RL, Storb U. Somatic
hypermutation of an immunoglobulin transgene
in kappa transgenic mice. Nature 1987;326:405–
409
care.diabetesjournals.org Chung and Associates 1635
